Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CpG

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: CpG. Displaying page 1 of 1.
    EudraCT Number: 2004-003813-18 Sponsor Protocol Number: C016 Start Date*: 2004-12-16
    Sponsor Name:Pfizer Inc
    Full Title: A continuation study of CPG 7909 Injection in patients with matastatic or recurrent malignancies who have stable disease or who have responded to CPG 7909 Injection therapy
    Medical condition: Patients with metastatic or recurrent malignancies who have stable disease or who have responded to CPG 7909 Injection therapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-004686-15 Sponsor Protocol Number: LUD 03-007 Start Date*: 2005-08-04
    Sponsor Name:Ludwig Institute For Cancer Research
    Full Title: Phase I/II study of immunization with multiple peptides mixed with the immunological adjuvant CpG 7909 in HLA-A2 patients with metastatic melanoma ...
    Medical condition: HLA-A2 patients with metastatic melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004684-30 Sponsor Protocol Number: LICR No.: LUD 02-001 Start Date*: 2005-08-04
    Sponsor Name:Ludwig Institute for Cancer Research
    Full Title: Phase I/II Studie zur Immunisierung mit dem Peptid MAGE-3.A1 gemischt mit der immunologischen Adjuvans CpG 7909 bei Patienten mit metastasiertem Melanom
    Medical condition: Phase I/II Studie zur Immunisierung mit dem MAGE-3.A1 Peptid gemischt mit der immunologischen Adjuvans CpG 7909 für Patienten mit metastastasiertem Melanom
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005389-11 Sponsor Protocol Number: VAC035 Start Date*: 2009-05-07
    Sponsor Name:University of Oxford
    Full Title: A Phase I/IIa Study of the Safety, Immunogenicity and Parasite Growth Inhibitory Activity of AMA1-C1/Alhydrogel® + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium falciparum Malaria
    Medical condition: Plasmodium falciparum malaria
    Disease: Version SOC Term Classification Code Term Level
    8.1 10036655 Prevention of malaria LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-004272-17 Sponsor Protocol Number: CLO-SCB-2019-003 Start Date*: 2021-03-25
    Sponsor Name:Clover Biopharmaceuticals AUS Pty Ltd
    Full Title: A Double-blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of CpG 1018/Alum-Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (S...
    Medical condition: SARS-CoV-2-mediated COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002818-13 Sponsor Protocol Number: DEALSZ-2021-001 Start Date*: 2023-05-12
    Sponsor Name:Charité-Universitätsmedizin Berlin
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 2, 12-Week Treatment Study with a 10-Week Follow-up Period to Assess the Efficacy and Safety of Benralizumab (anti-IL5Rα) in Adult Patients wit...
    Medical condition: Chronic prurigo in adult patients. Chronic Prurigo is characterized by the presence of chronic pruritus, multiple localized or generalized, pruriginous lesions, and the history and/or signs of a p...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037083 Prurigo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004007-64 Sponsor Protocol Number: 111476 Start Date*: 2009-07-16
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma
    Medical condition: First-line treatment for patients with unresectable, MAGE-A3-positive stage III or stage IVa melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IE (Completed) FR (Completed) ES (Completed) IT (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2013-001060-38 Sponsor Protocol Number: DECO Start Date*: 2013-05-28
    Sponsor Name:Academic Medical center
    Full Title: Pre-operative Decitabine in colon cancer: a proof of principal study
    Medical condition: colon cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001159-20 Sponsor Protocol Number: STH14404 Start Date*: 2008-09-25
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: A Prospective, Multi-centre, Single-Arm, Open Label Study of the Long term Use of a LHRH Agonist (Decapeptyl® SR, 11.25 mg) in Combination with Livial® Add-back Therapy in the Management of Chronic...
    Medical condition: Chronic cyclical pelvic pain
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038604 - Reproductive system and breast disorders 10064189 Chronic pelvic pain syndrome LLT
    13.1 10038604 - Reproductive system and breast disorders 10014778 Endometriosis PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000712-30 Sponsor Protocol Number: ABR-71432 Start Date*: 2021-06-07
    Sponsor Name:Radboudumc
    Full Title: Targeted glucocorticoid administration to improve safety learning in PTSD patients with HPA axis dysregulation
    Medical condition: Posttraumatic Stress Disorder (PTSD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10036876 Prolonged posttraumatic stress disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000035-23 Sponsor Protocol Number: VLA2001-307 Start Date*: 2022-04-11
    Sponsor Name:Valneva Austria GmbH
    Full Title: OPEN-LABEL PHASE 2/3 CLINICAL STUDY TO INVESTIGATE SAFETY AND IMMUNOGENICITY OF A SINGLE VLA2001 BOOSTER VACCINATION IN ADULT VOLUNTEERS, AFTER RECEIPT OF NATIONALLY ROLLED OUT MRNA COVID-19 VACCI...
    Medical condition: Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness a...
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084458 COVID-19 prophylaxis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002324-41 Sponsor Protocol Number: PH2/051 Start Date*: 2006-11-30
    Sponsor Name:Cancer Research UK
    Full Title: A Cancer Research UK Randomised Multicentre Phase II Trial of the DNA-hypomethylating Agent, 5-Aza-2'-deoxycytidine(Decitabine) given intravenously in Combination with Carboplatin, versus Carboplat...
    Medical condition: Progressive, advanced ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033128 Ovarian cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004555-35 Sponsor Protocol Number: A8501001 Start Date*: 2005-12-15
    Sponsor Name:Pfizer Inc
    Full Title: International, randomized, open-label, Phase 3 trial of paclitaxel/carboplatin plus PF-3512676 versus paclitaxel/carboplatin alone as first-line treatment of patients with advanced non-small cell l...
    Medical condition: First line treatment of chemotherapy-naive patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV) Non Small Cell Lung Cancer (NSCLC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Completed) HU (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) BE (Completed) PT (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004557-10 Sponsor Protocol Number: A8501002 Start Date*: 2006-02-21
    Sponsor Name:Pfizer Inc
    Full Title: International, randomized, open-label, Phase 3 trial of gemcitabine/cisplatin plus PF-3512676 versus gemcitabine/cisplatin alone as first-line treatment of patients with advanced non-small cell lun...
    Medical condition: First line treatment of chemotherapy-naive patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV) Non Small Cell Lung Cancer (NSCLC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SK (Completed) ES (Completed) HU (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) AT (Completed) PT (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023584-17 Sponsor Protocol Number: RAS-AZIC Start Date*: 2012-08-31
    Sponsor Name:Universität Leipzig
    Full Title: Response-Adapted Sequential Azacitidine And Chemotherapy in Patients > 60 Years Old With Newly Diagnosed AML Eligible for Chemotherapy and allogeneic hematopoietic cell transplantation: A Multicent...
    Medical condition: acute myeloid leukeamia
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001138-40 Sponsor Protocol Number: IOM-605 Start Date*: 2011-11-17
    Sponsor Name:iOMEDICO AG
    Full Title: First Line Pazopanib in Poor Risk Patients with Metastatic Renal Cell Carcinoma
    Medical condition: Locally advanced or metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10038407 Renal cell cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016636-13 Sponsor Protocol Number: 113173 Start Date*: 2010-06-28
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open, dose-escalation Phase I/II study to assess the safety, immunogenicity and clinical activity of recPRAME + AS15 Antigen-Specific Cancer Immunotherapeutic as first-line treatment of patients...
    Medical condition: First-line treatment of patients with PRAME-positive unresectable stage III or IV metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2006-001588-52 Sponsor Protocol Number: A8501004 Start Date*: Information not available in EudraCT
    Sponsor Name:Pfizer Pharma GmbH
    Full Title: A randomized phase II trial of pemetrexed with or without PF-3512676 for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of one prior chemothe...
    Medical condition: Treatment of patients with locally advanced or metastatic non-small lung cancer (NSLC) after failure of one prior chemotherapy regimen for advanced disease
    Disease: Version SOC Term Classification Code Term Level
    Med 10061873 VTc
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Feb 09 08:04:16 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA